BOSTON, SAN FRANCISCO and LONDON, Jan. 6, 2011 /PRNewswire/ —
SV Life Sciences (“SVLS”) today announced the promotion of Paul
LaViolette to Partner. Mr. LaViolette joined SVLS in early 2009 as
Venture Partner.
“Since joining SVLS, Paul has successfully applied his
tremendous experience with large-scale medical technology
businesses to our portfolio of development stage companies,” said
David Milne, SVLS Managing Partner. “In doing so, Paul has
underscored a key component to the SVLS value proposition.
Consistently, we have attracted highly talented healthcare
operators and executives from the life sciences fields and made
them long-term members of our investment team. I know I speak on
behalf of the entire firm in congratulating Paul on his
promotion.”
At SVLS, Mr. LaViolette has attracted novel deal flow that has
led to multiple new investments and investment options. He has
assumed board and advisory roles for a number of existing SVLS
portfolio companies including TransEnterix, CardioFocus, ValenTx,
MindFrame and Altura Medical. In addition to these positions, he
serves on the boards of Cameron Health, Conceptus, DC Devices,
Direct Flow Medical, DJO Global, Thoratec, Trans 1, and the Medical
Device Manufacturers Association (MDMA), giving him broad and
ongoing exposure to the medical device and technology
industries.
Mr. LaViolette has 30 years of global medical technology
marketing and general management experience. Most recently, he was
with Boston Scientific Corporation, where he served as COO, Group
President, President-Cardiology and President-International. During
his tenure, the Company grew revenues over 20 times. He also
spearheaded over 20 acquisitions and led extensive product
development, operations and worldwide commercial organizations.
Prior to that, he held marketing and general management
positions at CR Bard and various marketing roles at Kendall
(Covidien). Mr. LaViolette has also served on the boards of
Urologix
‘/>”/>